Status:

UNKNOWN

Measurement of Expiratory Flow Variability for the Detection of Bronchospasm in Infants Using the Ventica® Device by Revenio

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborating Sponsors:

Revenio Research

Conditions:

Healthy, Wheezing, Non Wheezing Acute Respiratory Episode

Eligibility:

All Genders

2-36 years

Brief Summary

Wheezing in infants and children less than 3 years of age children is a frequent feature that might be difficult to diagnose when only the caregivers reporting is available. Indeed, in this age group ...

Detailed Description

Decrease airway caliber induces airflow limitation which, in turn, will determine a decrease in the tidal breathing variability. While sleeping, tidal breathing variability will not be influenced by e...

Eligibility Criteria

Inclusion

  • For all children, 2 to 36-months-olds, term birth (\> 37 ga), birth weight \> 3 Percentile, no hospitalisation for newborn respiratory distress, family aware of the use of the medical device, family of legal guardian consent to the study. According to the group, group 1: no history of chronic rhinitis, bronchiolitis or asthma, no respiratory allergy, no current acute disease, group 2: no history of chronic rhinitis, bronchiolitis or asthma, no respiratory allergy, no history of chronic rhinitis, bronchiolitis or asthma, no respiratory allergy, presence of current non-wheezing respiratory disease or fever, group 3: presence of current wheezing episode

Exclusion

  • Tonsil hypertrophy with respiratory impact
  • Clinical sleep apnea syndrome (snoring or apnea noted or breathing obstructed during sleep)
  • Use of rapid onset bronchodilator for less than 8 hours (except for asthmatic infants included in an exacerbation)
  • Anti-asthma treatment in progress (except for asthmatic infants included during an exacerbation)
  • Known chronic cardio-respiratory or other pathology that may have a respiratory impact.
  • Skin pathology preventing DM placement
  • Patients with a pacemaker, continuous glucose monitor, or any other connected or implanted electronic or other medical device (e.g. ECG)

Key Trial Info

Start Date :

March 7 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

March 7 2024

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT04702620

Start Date

March 7 2022

End Date

March 7 2024

Last Update

April 18 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Armand Trousseau Hospital

Paris, France, 75012